PT  - JOURNAL ARTICLE
AU  - Ganesh Raghu
TI  - Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
AID  - 10.1183/16000617.0071-2017
DP  - 2017 Sep 30
TA  - European Respiratory Review
PG  - 170071
VI  - 26
IP  - 145
4099  - http://err.ersjournals.com/content/26/145/170071.short
4100  - http://err.ersjournals.com/content/26/145/170071.full
SO  - EUROPEAN RESPIRATORY REVIEW2017 Sep 30; 26
AB  - Over the past two and a half decades, many clinical trials have been designed to determine the safety and efficacy of pharmacotherapy for patients with idiopathic pulmonary fibrosis (IPF). However, so far, only two drugs (pirfenidone and nintedanib) have been found to have an impact on disease progression as defined by reducing the rate of decline in forced vital capacity over a year among IPF patients with mild to moderate impairment in lung function. These two drugs have been approved for treatment of IPF by regulatory agencies and are currently in clinical use worldwide. This article summarises the current landscape of pharmacotherapy for IPF and highlights the prospects and potential of new therapies that are currently being pursued in clinical trials.The landscape of treatment for IPF is on new turf with nintedanib, pirfenidone and new clinical trials http://ow.ly/bav230eQPgl